Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go

[en] Spinal muscular atrophy (SMA) is a rare and devastating disease. New disease- modifying treatments have recently been approved and early treatment has been related to a better outcome. In this context, several newborn screening (NBS) programs have been implemented. The aim of the study was to obtain a global overview on the current situation and perspectives on SMA NBS. We conducted a survey and contacted experts from 152 countries, from which we gathered 87 responses. We identified 9 SMA NBS programs that have so far detected 288 newborns with SMA out of 3,674,277 newborns screened. Funding, screening methods, organisation, and consent process were variable between SMA NBS programs. Many respondents pointed the lack of cost/benefit data as a major obstacle to SMA NBS implementation. In the next four years, our data suggest a 24 % coverage of newborns from countries where a disease-modifying drug is available and 8,5 % coverage in countries with no diseases-modifying drugs. The annual proportion of newborns to be screened in the coming years is expected to increase steadily. The experts expressed a strong need for the implementation of SMA NBS as means to improve care for patients with SMA.

Disciplines :

Neurology

Author, co-author :

Dangouloff, Tamara ; Université de Liège - ULiège > Département des sciences cliniques > Neuropédiatrie

Vrščaj, Eva; University Children’s Hospital, University Medical Centre Ljubljana, Slovenia > Department of Pediatric Neurology

Servais, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > Département de Pédiatrie > Service de pédiatrie

Osredkar, Damjan; University of Ljubljana, Slovenia > Medical Faculty

Language :

English

Title :

Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go

Publication date :

2021

Journal title :

Neuromuscular Disorders

ISSN :

0960-8966

eISSN :

1873-2364

Publisher :

Elsevier, Netherlands

Volume :

Issue :

Pages :

574 - 582

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 12 April 2021

Statistics

Number of views

111 (9 by ULiège)

Number of downloads

7 (7 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Verhaart, I.E.C., Robertson, A., Wilson, I.J., Aartsma-Rus, A., Cameron, S., Jones, C.C., et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis, 12, 2017, 124, 10.1186/s13023-017-0671-8.
D'Amico, A., Mercuri, E., Tiziano, F.D., Bertini, E., Spinal muscular atrophy. Orphanet J Rare Dis, 6, 2011, 71, 10.1186/1750-1172-6-71.
Wirth, B., An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 15 (2000), 228–237 10.1002/(sici)1098-1004(200003)15:3<228::Aid−humu3>3.0.Co;2-9.
Ramdas, S., Servais, L., New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin Pharmacother 21 (2020), 307–315, 10.1080/14656566.2019.1704732.
Finkel, R.S., Mercuri, E., Darras, B.T., Connolly, A.M., Kuntz, N.L., Kirschner, J., et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377 (2017), 1723–1732, 10.1056/NEJMoa1702752.
Mendell, J.R., Al-Zaidy, S., Shell, R., Arnold, W.D., Rodino-Klapac, L.R., Prior, T.W., et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377 (2017), 1713–1722, 10.1056/NEJMoa1706198.
Lowes, L., Al-Zaidy, S., Shell, R., Arnold, W., Rodino-Klapac, L., Prior, T., et al. AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: patients treated early with the proposed therapeutic dose were able to sit unassisted at a younger age. Neuromuscul Disord 27 (2017), S208–S209, 10.1016/j.nmd.2017.06.414.
Baranello G., Darras B., Day J., Deconinck N., Klein A., Masson R., et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med, in Press.
Dangouloff, T., Servais, L., Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag 15 (2019), 1153–1161, 10.2147/tcrm.S172291.
De Vivo D.C., Topaloglu H., Swoboda K.J., Bertini E., Hwu W.-.L., Crawford T.O., et al. Nusinersen in infants who initiate treatment in a presymptomatic stage of spinal muscular atrophy (SMA): interim efficacy and safety results from the phase 2 Nurture study (S25.001). Am Acad Neurol 2019 - 71st Annu Meet, n.d.
Dangouloff, T., Burghes, A., Tizzano, E.F., Servais, L., 244th ENMC International Workshop: newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands. Neuromuscul Disord 30 (2020), 93–103, 10.1016/j.nmd.2019.11.002.
Kariyawasam, D.S.T., Russell, J.S., Wiley, V., Alexander, I.E., Farrar, M.A., The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med 22 (2019), 557–565, 10.1038/s41436-019-0673-0.
Boemer, F., Caberg, J.-.H., Dideberg, V., Dardenne, D., Bours, V., Hiligsmann, M., et al. Newborn screening for SMA in Southern Belgium. Neuromuscul Disord 29 (2019), 343–349, 10.1016/j.nmd.2019.02.003.
McMillan, H.J., Kernohan, K.D., Yeh, E., Amburgey, K., Boyd, J., Campbell, C., et al. Newborn screening for spinal muscular atrophy: ontario testing & follow-up recommendations. Can J Neurol Sci Le J Can Des Sci Neurol, 2020, 1–24, 10.1017/cjn.2020.229.
Vill, K., Kolbel, H., Schwartz, O., Blaschek, A., Olgemoller, B., Harms, E., et al. One year of newborn screening for SMA - results of a german pilot project. J Neuromuscul Dis 6 (2019), 503–515, 10.3233/jnd-190428.
Shinohara, M., Niba, E.T.E., Wijaya, Y.O.S., Takayama, I., Mitsuishi, C., Kumasaka, S., et al. A novel system for spinal muscular atrophy screening in newborns: Japanese pilot study. Int J Neonatal Screen, 5, 2019, 41, 10.3390/ijns5040041.
Chien, Y.H., Chiang, S.C., Weng, W.C., Lee, N.C., Lin, C.J., Hsieh, W.S., et al. Presymptomatic diagnosis of spinal muscular atrophy through newborn screening. J Pediatr 190 (2017), 124–129, 10.1016/j.jpeds.2017.06.042 e1.
Kraszewski JN, Kay DM, Stevens CF, Koval C, Haser B, Ortiz V, et al. Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet Med 2017;10.1038/gim.2017.152. doi: 10.1038/gim.2017.152.
Harris, P.A., Taylor, R., Minor, B.L., Elliott, V., Fernandez, M., O'Neal, L., et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform, 95, 2019, 103208, 10.1016/j.jbi.2019.103208.
Nations U. Welcome to the United Nations. https://www.un.org/en/sections/about-un/overview/index.html (accessed December 1, 2020).
Chien, Y.-.H., Hwu, W.-.L., Lee, N.-.C., Newborn screening: Taiwanese experience. Ann Transl Med, 7, 2019, 281, 10.21037/atm.2019.05.47.
Chan, M.-.J., Liao, H.-.C., Gelb, M.H., Chuang, C.-.K., Liu, M.-.Y., Chen, H.-.J., et al. Taiwan National newborn screening program by tandem mass spectrometry for mucopolysaccharidoses types I, II, and VI. J Pediatr 205 (2019), 176–182, 10.1016/j.jpeds.2018.09.063.
Hwu, W.-L., Chien, Y.-H., Lee, N.-C., Chiang, S.-C., Dobrovolny, R., Huang, A.-C., et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 30 (2009), 1397–1405, 10.1002/humu.21074.
Dangouloff, T., Botty, C., Beaudart, C., Servais, L., Hiligsmann, M., Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis, 16, 2021, 47, 10.1186/s13023-021-01695-7.
Aharoni, S., Nevo, Y., Orenstein, N., Basel-Salmon, L., Ben-Shachar, S., Mussaffi, H., et al. Impact of a national population-based carrier-screening program on spinal muscular atrophy births. Neuromuscul Disord 30 (2020), 970–974, 10.1016/j.nmd.2020.10.005.
Kay, D.M., Stevens, C.F., Parker, A., Saavedra-Matiz, C.A., Sack, V., Chung, W.K., et al. Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy. Genet Med 8 (2020), 1296–1302, 10.1038/s41436-020-0824-3.
Edmondson, C., Grime, C., Prasad, A., Cowlard, J., Nwokoro, C.E.C., Ruiz, G., et al. Cystic fibrosis newborn screening: outcome of infants with normal sweat tests. Arch Dis Child 103 (2018), 753–756, 10.1136/archdischild-2017-313290.
Kay, D.M., Maloney, B., Hamel, R., Pearce, M., DeMartino, L., McMahon, R., et al. Screening for cystic fibrosis in New York State: considerations for algorithm improvements. Eur J Pediatr 175 (2016), 181–193, 10.1007/s00431-015-2616-3.
Buckley, R.H., The long quest for neonatal screening for severe combined immunodeficiency. J Allergy Clin Immunol 129 (2012), 597–606, 10.1016/j.jaci.2011.12.964.
Quinn, J., Orange, J.S., Modell, V., Modell, F., The case for severe combined immunodeficiency (SCID) and T cell lymphopenia newborn screening: saving lives…one at a time. Immunol Res 68 (2020), 48–53, 10.1007/s12026-020-09117-9.
International Monetary Fund. Country Composition of World Economic Outlook Groups 2020. https://www.imf.org/external/pubs/ft/weo/2020/02/weodata/groups.htm.